Tomocube (Co-CEOs Yonggeun Park and Kihyun Hong), a specialized company in three-dimensional label-free cell imaging, announced on the 25th that it has finalized its public offering price at 16,000 KRW, exceeding the upper limit of the expected price band (10,900 to 13,400 KRW), following a demand forecast conducted for domestic and international institutional investors.
During the five-day demand forecast from the 17th to the 23rd, 2,396 institutions from home and abroad participated, recording a competition rate of 967 to 1. Based on the finalized public offering price of 16,000 KRW, the total public offering amount is 32 billion KRW, and the market capitalization after listing is approximately 203.7 billion KRW. Among the institutions participating in the demand forecast, 99.7% proposed prices at or above the upper limit of the offering band based on their participation volume.
A representative from Daishin Securities, the lead underwriter, explained, “Many institutional investors highly valued Tomocube’s establishment of a solid entry barrier within the bioanalysis industry based on its Holotomography (HT) technology, as well as its broad expansion potential into non-bio fields such as hybrid bonding and semiconductor glass substrates. From the first day of the demand forecast, numerous institutional investors flocked and proposed prices exceeding the upper limit, showing high participation rates.”
Tomocube’s greatest competitive advantage lies in its proprietary Holotomography (HT) core technology. Holotomography is Tomocube’s unique technology that enables real-time, high-resolution observation of living cells or organoids without cell loss or deformation. Since Tomocube’s Holotomography is advantageous for real-time observation of 3D high-resolution images while cultivating organoids, which are human organ analogs, it has significant scalability. It is gaining attention in areas such as ▲organoids ▲IVF (in vitro fertilization) ▲cell therapy ▲new drug development, and recently, it has expanded beyond the bio sector into the hybrid bonding, semiconductor advanced packaging inspection market, and glass substrate (semiconductor glass substrate) inspection market, broadening its base.
Tomocube plans to use the funds raised through this listing to ▲enter global markets ▲expand capacity in response to front-end industry growth ▲and invest in research and development for product and business expansion, thereby laying the foundation for sustainable growth.
Yonggeun Park, CEO of Tomocube, stated, “We thank the investors who actively participated in the demand forecast, believing in Tomocube’s corporate value and growth potential. After listing, we will widely promote Tomocube’s Holotomography (HT) technology in the global market and become a global bioimaging company that provides technological standards in the rapidly growing organoid and cell therapy markets.”
Meanwhile, Tomocube is scheduled to conduct a general subscription over two days on the 28th and 29th, followed by a listing on the KOSDAQ market on November 7. The lead underwriter is Daishin Securities.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
